Creating World Driving ID Dx Progress

DUBLIN, Jan. 20, 2023 /PRNewswire/ — The “Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2022-2026” report has been added to ResearchAndMarkets.com’s providing.

COVID-19 Drives a surge in demand however what’s the long run impression? The microbiology lab could disappear whereas multiplex takes middle stage.

The Molecular Diagnostics – Infectious Illness sector of the medical diagnostics trade is poised for file development. A market that simply retains on rising however is spiking as an infinite C19Dx demand sweeps over the globe. Discover out what the numbers are on this informative report. And discover out concerning the thrilling developments in multiplex assays which threaten to vary analysis and therapy whereas limiting the specter of anti microbial drug resistance.

Infectious illness testing straight advantages from the explosion in biotechnology, particularly genomics. Be taught all about it on this report. A spread of dynamic traits are pushing market development and firm valuations.

Developments like:

• Multiplex testing

• pathogen evolution and pandemics

• biotechnology advances in genetics

• local weather change

• globalization

• the rise of speedy testing

Thrilling technical developments particularly within the seesaw between nucleic acid testing and immunoassay, maintain the promise of a dynamic, rising and evolving world market that holds the promise of diagnostics taking the lead in infectious illness eradication.

The report has lots of of pages of data together with a whole record of Present United States Medicare Charge Cost Schedules to assist sharpen your pricing. Once more, help in utilizing the knowledge is generally supplied with out further fees. The report contains detailed breakouts for 15 International locations and 4 Areas. An in depth breakout for any nation on the planet is obtainable to purchasers of the report.

All report information is obtainable in Excel format on request.

The report contains 5 yr market forecasts.

Key Subjects Lined:

1 Market Guides
1.1 Strategic Scenario Evaluation and Impression of COVID-19.
1.2 Information for Executives, Advertising and marketing, Gross sales and Enterprise Improvement Workers
1.3 Information for Administration Consultants and Funding Advisors

2 Introduction and Market Definition

3 The Infectious Ailments – Market Evaluation by Illness
3.1 HIV – Human Immunodeficiency Virus (AIDS)
3.2 HBV – Hepatitis B
3.3 HCV – Hepatitis C
3.4 HPV – Human papillomavirus
3.5 Influenza
3.6 CTGC – Chlamydia/Gonorrhoea
3.7 Tuberculosis
3.8 MRSA – Methicillin-resistant Staphylococcus aureus
3.9 VRE – Vancomycin-resistant Enterococcus
3.10 Blood Screening
3.11 COVID-19
3.12 Pandemic Diagnostics

4 Trade Overview
4.1 Gamers in a Dynamic Market
4.1.1 Educational Analysis Lab
4.1.2 Diagnostic Check Developer
4.1.3 Instrumentation Provider
4.1.4 Distributor and Reagent Provider
4.1.5 Unbiased Testing Lab
4.1.6 Public Nationwide/regional lab
4.1.7 Hospital lab
4.1.8 Doctor Workplace Labs
4.1.9 Audit Physique
4.1.10 Certification Physique
4.2 The Medical Laboratory Market Segments
4.2.1 Conventional Market Segmentation
4.2.2 Laboratory Focus and Segmentation
4.3 Trade Construction
4.3.1 Hospital Testing Share
4.3.2 Economies of Scale
4.3.2.1 Hospital vs. Central Lab
4.3.3 Doctor Workplace Lab’s
4.3.4 Physicians and POCT

5 Profiles of Key MDx Corporations
5.1 1928 Diagnostics
5.2 Abacus Diagnostica
5.3 Abbott Laboratories
5.4 Speed up Diagnostics
5.5 Entry Bio
5.6 Ador Diagnostics
5.7 ADT Biotech
5.8 Akonni Biosystems
5.9 Altona Diagnostics
5.10 Alveo Applied sciences
5.11 Anatolia Geneworks
5.12 Antelope Dx
5.13 Utilized BioCode
5.14 Assurance Scientific Laboratories
5.15 Aureum Diagnostics
5.16 Aus Diagnostics
5.17 Beckman Coulter Diagnostics
5.18 Becton, Dickinson and Firm
5.19 Binx Well being
5.20 Biocartis
5.21 BioFire Diagnostics (bioMerieux)
5.22 bioMerieux Diagnostics
5.23 Bio-Rad Laboratories, Inc
5.24 Bosch Healthcare Options GmbH
5.25 Celemics
5.26 Cepheid (Danaher)
5.27 Chembio
5.28 Co Diagnostics
5.29 Credo Diagnostics Biomedical
5.30 Cue Well being
5.31 Curetis N.V./Curetis GmbH
5.32 Detect
5.33 Diagenode Diagnostics
5.34 Diascopic
5.35 Diasorin S.p.A.
5.36 Eiken Chemical
5.37 Enzo Biochem
5.38 Eurofins Scientific
5.39 Fluxergy
5.40 Fulgent Genetics
5.41 Fusion Genomics.
5.42 Genedrive
5.43 Genetic Signatures
5.44 GenMark Dx (Roche)
5.45 Grifols
5.46 Grip Molecular Applied sciences
5.47 Hibergene Diagnostics
5.48 Hologic
5.49 Illumina
5.50 Immunexpress
5.51 Inflammatix
5.52 Invetech
5.53 Janssen Diagnostics
5.54 Karius
5.55 Lexagene
5.56 LightDeck Diagnostics
5.57 Lucira Well being
5.58 Luminex Corp
5.59 LumiraDx
5.60 Lumos Diagnostics
5.61 Mammoth Biosciences
5.62 Maxim Biomedical
5.63 Meridian Bioscience
5.64 Mesa Biotech (Thermo Fisher)
5.65 Millipore Sigma
5.66 Mindray
5.67 Mobidiag (Hologic)
5.68 Molbio Diagnostics
5.69 Nanomix
5.70 Novacyt
5.71 Novel Microdevices
5.72 Operon
5.73 Oxford Nanopore Applied sciences
5.74 Panagene
5.75 Pathogenomix
5.76 Perkin Elmer
5.77 Prenetics
5.78 Primerdesign (Novacyt)
5.79 Prominex
5.80 Qiagen
5.81 QuantuMDx
5.82 Quest Diagnostics
5.83 Quidel
5.84 Randox Toxicology
5.85 Roche Molecular Diagnostics
5.86 Noticed Diagnostics
5.87 SD Biosensor
5.88 Seegene
5.89 Siemens Healthineers
5.90 SomaLogic
5.91 Sona Nanotech
5.92 SpeeDx
5.93 T2 Biosystems
5.94 Talis Biomedical
5.95 Thermo Fisher Scientific Inc.
5.96 Veramarx
5.97 Veredus Laboratories
5.98 Vir
5.99 Vircell
5.100 Visby Medical
5.101 XCR Diagnostics
5.102 YD Diagnostics
5.103 Zhejiang Orient Gene Biotech

6 Market Developments
6.1 Elements Driving Progress
6.1.1 New Genotypes Creating New Markets
6.1.2 Getting older Inhabitants a Boon for All Diagnostics
6.1.3 Creating World Driving ID Dx Progress
6.1.4 Level of Care – Why Centralization is Shedding Steam
6.1.5 Self Testing
6.1.6 The Want for Pace
6.1.7 The COVID Pandemic
6.2 Elements Limiting Progress
6.2.1 Decrease Prices
6.2.2 Infectious Illness is Declining
6.2.3 Wellness Hurts
6.2.4 Financial Progress improves Dwelling Requirements
6.3 Instrumentation and Automation
6.3.1 Devices Key to Market Share
6.3.2 The Shrinking Machine
6.3.3 Multiplex, Level of Care and The Pace Issue
6.4 Diagnostic Expertise Improvement
6.4.1 The Sepsis Testing Market – A New Path?
6.4.2 POCT/Self Testing as a Disruptive Power
6.4.3 The Genetics Play – One Check for All Recognized Infections
6.4.4 Antibiotic Resistance Genes – Simplifying Diagnostics

7 Molecular Dx – Infectious Illness Latest Developments
7.1 Latest Developments – Significance and The way to Use This Part
7.1.1 Significance of These Developments
7.1.2 The way to Use This Part
7.2 BioMerieux Invests in Sepsis Dx Startup Weezion
7.3 Domus Diagnostics to Launch POC MDx Check System
7.4 Proof Dx Plans Infectious Illness, Oncology Exams for CRISPR-Based mostly POC
7.5 Oxford Nanopore Diagnostics to Develop Medical Instruments
7.6 Pathogenomix Creating Infectious Illness Platform Utilizing NGS
7.7 COVID-19 Accelerating Pattern Towards Pharmacy-Based mostly Testing
7.8 Co-Diagnostics Seeks FDA EUA for At-Dwelling PCR Diagnostic
7.9 Sense Biodetection to Debut Instrument-Free Level-of-Care MDx
7.10 Dwelling Check Firm Prenetics to go Public
7.11 Roche to Purchase TIB Molbiol to Increase Infectious Illness Portfolio
7.12 Lucira Well being Posts Income Progress on OTC C19 Check
7.13 BforCure Getting ready A number of Panels for Level-of-Care qPCR Platform
7.14 Talis Biomedical Discusses Level-of-Care
7.15 Roche to Purchase GenMark Diagnostics for $1.8B
7.16 Pandemic Pushes Handheld qPCR Units Nearer to Commercialization
7.17 Hologic to Purchase Mobidiag
7.18 Lucira Well being Focuses on Consumer Pleasant Strategy to Dwelling Testing
7.19 Infectious Illness Dx Agency Talis Biomedical Raises $254M in IPO
7.20 Fluidigm Plans ‘Sturdy’ Diagnostics, Medical Enterprise
7.21 Thermo Fisher Scientific to Purchase Mesa Biotech for As much as $550M
7.22 Mammoth Biosciences Creating Pathogen Detection Tech
7.23 Illumina, IDbyDNA Creating Sequencing-Based mostly Respiratory Exams
7.24 Scanogen Creating 90 Minute An infection Check
7.25 Malaria Assays Use CRISPR for Level-of-Care Multispecies Detection
7.26 FDA Supplies Self Testing SARS-CoV-2 EAU Steerage
7.27 Mammoth Biosciences Broadcasts Fast, CRISPR-Based mostly COVID-19 Diagnostic
7.28 Genetic Signatures Will get CE Mark for Coronavirus Molecular Check
7.29 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
7.30 Lumos Diagnostics Closes $15M Sequence A Funding
7.31 Fusion Genomics to Assess NGS-Based mostly Respiratory Tract An infection Assay

8 The World Marketplace for Molecular Diagnostics Infectious Illness
8.1 World Market Overview by Nation
8.2 World Market by Syndrome – Overview
8.3 World Market by Plex – Overview
8.4 World Market by Place – Overview

9 World MDx Infectious Illness Markets – By Syndrome

10 World MDx Markets for Infectious Illness – by Plex

11 World MDx Infectious Illness Markets – by Place

12 Appendices

For extra details about this report go to https://www.researchandmarkets.com/r/rb5pu2

Media Contact:

Analysis and Markets 
Laura Wooden, Senior Supervisor 
[email protected]

For E.S.T Workplace Hours Name +1-917-300-0470 
For U.S./CAN Toll Free Name +1-800-526-8630 
For GMT Workplace Hours Name +353-1-416-8900

U.S. Fax: 646-607-1907 
Fax (outdoors U.S.): +353-1-481-1716

Emblem: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

View authentic content material:https://www.prnewswire.com/news-releases/worldwide-molecular-diagnostics-for-infectious-disease-industry-report-2022-developing-world-driving-id-dx-growth-301726669.html

SOURCE Analysis and Markets